drugset
drugset / Trial / NCT05140096

A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants

NCT05140096 ↗

Phase 1 Completed 30 enrolled Acerta Pharma BV
RandomizedSequentialOpen-labelTreatment

Summary

This study will evaluate the effect of fluconazole and isavuconazole on the PK of acalabrutinib and its active metabolite, ACP-5862.

Timeline

Start
2020-01-03
Primary completion
2020-04-15
Completion
2020-04-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Acalabrutinib Small molecule 100 mg Oral
Subject Fluconazole Small molecule 400 mg Oral
Subject Isavuconazole Small molecule 200 mg Oral

Indications

No indication recorded.